Hypothesis Comparison

⚛ Collide these ⚔ Judge as Duel

Comparing 2 hypotheses side-by-side

|

H2S/butyrate imbalance drives enteric alpha-synuclein pathology via TLR4 signali

SNCA · Parkinson's disease · mechanistic
Composite
0.000
Price
$0.50
Evidence For
0
Evidence Against
0

In Parkinson's disease, elevated H2S-producing Desulfovibrio species and depleted butyrate-producing Faecalibacterium prausnitzii create a metabolite imbalance that simultaneously disrupts gut barrier integrity and increases systemic LPS translocation. The resulting TLR4 activation on enteric neurons triggers NF-κB-mediated neuroinflammation, promoting local alpha-synuclein misfoldling and aggregation. This enteric pathology then propagates bidirectionally along the vagus nerve to the dorsal mot

Physiological SCFAs may reduce alpha-synuclein burden primarily through a gut-fi

SNCA · neurodegeneration · -
Composite
0.650
Price
$0.65
Evidence For
0
Evidence Against
0

Low-micromolar systemic SCFA exposure is unlikely to directly drive substantia nigra alpha-synuclein clearance, but colon and enteric nervous system compartments experience much higher local exposure and may show reduced pS129-alpha-syn, lower seeding pressure, and delayed gut-to-brain propagation. This is the strongest translationally credible hypothesis because it matches exposure reality and explains why dietary or microbiome interventions could matter without requiring pharmacologic brain co

Convergent vs Divergent Predictions

This summary checks where the selected hypotheses point toward the same target or mechanism, and where they pull in opposite directions.

SNCAGut Microbiome NeuroinflammationUnspecified Mechanism
Convergent signals
  • SNCA recurs across 2 selected hypotheses with aligned directionality in gut microbiome neuroinflammation, unspecified mechanism.
Divergent signals
  • No direct polarity conflicts detected among the selected hypotheses.

Verdict Summary

4/11
dimensions won
H2S/butyrate imbalance drives enteric al
8/11
dimensions won
Physiological SCFAs may reduce alpha-syn

Radar Chart — 10 Dimensions

Score Comparison Bars

Mechanistic
0.72
0.82
Evidence
0.72
0.63
Novelty
0.78
0.66
Feasibility
0.82
0.74
Impact
0.00
0.67
Druggability
0.00
0.58
Safety
0.00
0.64
Competition
0.00
0.61
Data
0.00
0.57
Reproducible
0.00
0.53
KG Connect
0.50
0.50

Score Breakdown

DimensionH2S/butyrate imbalance drives Physiological SCFAs may reduce
Mechanistic0.7200.820
Evidence0.7200.630
Novelty0.7800.660
Feasibility0.8200.740
Impact0.0000.670
Druggability0.0000.580
Safety0.0000.640
Competition0.0000.610
Data0.0000.570
Reproducible0.0000.530
KG Connect0.5000.500

Evidence

H2S/butyrate imbalance drives enteric alpha-synuclein pathol

No evidence citations yet

Physiological SCFAs may reduce alpha-synuclein burden primar

No evidence citations yet

Debate Excerpts

Physiological SCFAs may reduce alpha-synuclein bur

4 rounds · quality: 0.63

Theorist

Below, I assume the key translational question is whether **physiologically achievable circulating SCFAs (roughly low-μM, especially for butyrate/propionate outside the colon)** can alter **α-synuclei...

Skeptic

**Overall** The main weakness across all six hypotheses is the same: the cited literature mostly shows that SCFAs can change PD-like phenotypes under model-specific, often pharmacologic conditions, bu...

Domain Expert

Physiologic low-μM systemic SCFAs do not look like a standalone drug-ready route for driving meaningful brain α-syn clearance. The surviving ideas are narrower: a gut-first signaling effect, a GLP-1-l...

Synthesizer

{ "ranked_hypotheses": [ { "title": "Physiological SCFAs may reduce alpha-synuclein burden primarily through a gut-first or ENS-first mechanism rather than direct brain exposure", "d...

Price History Overlay